IMPAX Receives Final FDA Approval for Generic Version Of Agrylin; Third Approval in 2005

April 18, 2005

HAYWARD, Calif.--(BUSINESS WIRE)--April 18, 2005--IMPAX Laboratories, Inc. (NASDAQ:IPXLE) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval to the Company's Abbreviated New Drug Application for a generic version of Agrylin(R) (Anagrelide Hydrocloride) HCI 0.5 and 1.0 mg capsules. Shire Pharmaceuticals markets Agrylin for the treatment of thrombocytosis and essential thrombocythaemia. U.S. sales of Agrylin HCI 0.5 and 1.0 mg capsules were approximately $109 million in the 12 months ended December 31, 2004, according to NDCHealth. IMPAX's Global Pharmaceuticals division intends to begin marketing this product immediately.

"We are pleased to have received this approval, our third of 2005," said Larry Hsu, Ph.D. Impax's President. "This is a further step in our strategy to commercialize niche pharmaceuticals."

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Impax's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, possible adverse effects resulting from Impax's delay in filing its 2004 Form 10-K including possible delisting from the NASDAQ National Market, Impax's ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, Impax's ability to successfully develop and commercialize pharmaceutical products, Impax's reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in Impax's filings with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and Impax undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

CONTACT: Company Contacts:
IMPAX Laboratories, Inc.
Barry R. Edwards, CEO, (215) 933-0323 Ext. 4360
Larry Hsu, Ph.D., President, (510) 476-2000 Ext. 1111
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, (212) 838-3777
Bruce Voss, (310) 691-7100

SOURCE: IMPAX Laboratories, Inc.